1.

Record Nr.

UNINA9910783307403321

Autore

Deyo Richard A

Titolo

Hope or hype [[electronic resource] ] : the obsession with medical advances and the high cost of false promises / / Richard A. Deyo, Donald L. Patrick

Pubbl/distr/stampa

New York, : AMACOM, American Management Association, c2005

ISBN

1-281-12625-X

9786611126254

0-8144-2859-2

Descrizione fisica

1 online resource (352 p.)

Altri autori (Persone)

PatrickDonald L

Disciplina

610/.28

Soggetti

Medical innovations - United States - Evaluation

Medical technology - United States - Evaluation

Medical care - Technological innovations - United States - Evaluation

Medical care - United States - Evaluation

Medical innovations - Economic aspects - United States

Medical technology - United States - Cost effectiveness

Medical care - Technological innovations - United States - Cost effectiveness

Medical care, Cost of - United States

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Bibliographic Level Mode of Issuance: Monograph

Nota di bibliografia

Includes bibliographical references (p. [291]-326) and index.

Nota di contenuto

Can there be too much of a good thing? the hazards of uncritically embracing medical advances -- What's the problem? don't we need lifesaving new treatments? -- Medical innovations and American culture: the call of the sirens -- Why more isn't always better: red herrings, side effects, and superbugs -- Why newer isn't always better: unpleasant surprises, recalls, and learning curves -- Social hazards: what we lose by uncritical use of new treatments -- How things really work: opinion makers and regulators of medical  advances -- What will you swallow? how drug companies get you to buy more expensive drugs than you may need -- Making friends, playing monopoly, and dirty tricks: other industry strategies -- Stacking the deck? how to get the "right" answer in clinical research -- "Cancer cured--film at 11:00":



the media's role in disseminating medical advances -- Doctors and hospitals: fueling the drive for new and more -- Advocacy groups: Mother Teresa's waiting room -- Holes in the safety net: the FDA and the FTC -- Ineffective. inferior or needlessly costly new drugs -- Medical devices that disappoint -- Ineffective or needlessly extensive surgery -- Weight loss technology: shedding pounds from your waistline or your wallet? -- For doctors: evidence-based medicine -- For insurers and researchers: pay now or pay more later -- For all decision makers: getting value for money -- For government: regulatory approaches to improve the dissemination of medical innovations -- For consumers: shared decision making.

Can there be too much of a good thing? the hazards of uncritically embracing medical advances -- What's the problem? don't we need lifesaving new treatments? -- Medical innovations and American culture: the call of the sirens -- Why more isn't always better: red herrings, side effects, and superbugs -- Why newer isn't always better: unpleasant surprises, recalls, and learning curves -- Social hazards: what we lose by uncritical use of new treatments -- How things really work: opinion makers and regulators of medical  advances -- What will you swallow? how drug companies get you to buy more expensive drugs than you may need -- Making friends, playing monopoly, and dirty tricks: other industry strategies -- Stacking the deck? how to get the "right" answer in clinical research -- "Cancer cured--film at 11:00": the media's role in disseminating medical advances -- Doctors and hospitals: fueling the drive for new and more -- Advocacy groups: Mother Teresa's waiting room -- Holes in the safety net: the FDA and the FTC -- Useless, harmful, or marginal: popular treatments that caused unnecessary disability, dollar costs, or death -- Ineffective or inferior new drugs -- Medical devices that disappoint -- Ineffective or needlessly extensive surgery -- Weight loss technology: shedding pounds from your waistline or your wallet? -- Crossing the threshold: improving the transition from "experimental" to "standard care" -- For doctors: evidence-based medicine -- For insurers and researchers: pay now or pay more later -- For all decision makers: getting value for money -- For government: regulatory approaches to improve the dissemination of medical innovations -- For consumers: shared decision making.